+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioengineered Protein Drugs Market - Global Forecast 2026-2032- Product Image
Bioengineered Protein Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Bioengineered Protein Drugs Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011369
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioengineered Protein Drugs Market is projected to reach USD 412.84 Billion in 2026. It is expected to continue growing at a CAGR of 7.52%, reaching USD 640.21 Billion by 2032.

Bioengineered Protein Drugs: Executive Overview

Bioengineered protein drugs include therapeutic proteins designed, produced, or modified through biological engineering, including recombinant proteins, monoclonal antibodies, fusion proteins, enzymes, and engineered cytokines. Their clinical value is supported by high target specificity and the ability to replace, supplement, or modulate biological functions. Development priorities increasingly center on improving efficacy, safety, durability, immunogenicity profiles, and patient convenience while addressing complex manufacturing and delivery requirements.

Transformative Shifts Reshaping Protein Therapeutics

The field is shifting from conventional replacement therapies toward engineered molecules with optimized binding, half-life, tissue penetration, and immune modulation. Advances in cell-line development, upstream and downstream bioprocessing, formulation science, and analytical characterization are enabling more consistent production and more demanding molecular designs. At the same time, subcutaneous delivery, autoinjectors, long-acting formulations, and combination regimens are influencing treatment selection by reducing administration burden. Regulatory attention remains focused on comparability, immunogenicity, process control, and evidence of clinical benefit.

Artificial Intelligence Accelerates Discovery, Development, and Manufacturing

Artificial intelligence is increasingly applied to protein sequence design, structure prediction, developability screening, biomarker identification, clinical-trial recruitment, and process optimization. Machine-learning systems can help prioritize candidate molecules, identify potential aggregation or immunogenicity risks, and analyze high-dimensional biological data. In manufacturing, data-driven monitoring may improve deviation detection and process understanding. However, effective adoption depends on validated datasets, explainable decision-making, secure data infrastructure, laboratory confirmation, and regulatory acceptance of AI-supported evidence.

Regional Insights Across the Global Protein-Drug Ecosystem

North America combines advanced biopharmaceutical research, specialized manufacturing, sophisticated clinical infrastructure, and established reimbursement pathways. Europe benefits from strong translational science, coordinated regulatory expertise, and substantial biologics manufacturing capabilities, although national assessment and reimbursement processes differ. Asia-Pacific is expanding research, manufacturing, and clinical-trial capacity, with China, Japan, South Korea, Australia, and India contributing distinct strengths. Latin America is increasing its role in clinical research, local production, and access programs while managing affordability and regulatory variation. The Middle East is developing specialized healthcare and life-science infrastructure, particularly in major Gulf markets. Africa presents important unmet medical needs and growing clinical and manufacturing capabilities, but access, supply-chain resilience, and specialized workforce constraints remain significant considerations.

Group-Level Perspectives on Policy, Trade, and Innovation

ASEAN markets offer a diverse combination of growing healthcare demand, manufacturing potential, and varied regulatory maturity, making harmonization and workforce development important priorities. BRICS countries bring substantial scientific, industrial, and healthcare-system diversity, with opportunities linked to local production and expanded access alongside differences in regulatory and reimbursement environments. The European Union benefits from shared scientific and regulatory frameworks, while national pricing and health-technology-assessment decisions remain influential. G7 economies generally provide deep research capacity, advanced care systems, and mature biologics oversight. GCC members are investing in healthcare modernization, specialized services, and supply resilience. NATO countries collectively represent important biomedical research and manufacturing capabilities, although the group’s security and policy agenda is broader than pharmaceutical development.

Country-Level Priorities and Operating Conditions

The United States remains important for protein-drug discovery, clinical development, advanced manufacturing, and specialist care. Canada contributes strong academic research and biotechnology capabilities. Brazil and Mexico are significant Latin American markets for clinical research, public-sector procurement, and local access strategies. China combines extensive research, manufacturing, and healthcare-system development, while India contributes pharmaceutical engineering, biosimilar expertise, and expanding clinical capabilities. Japan emphasizes high-quality biologics development and an aging-population healthcare context; South Korea is strengthening biologics manufacturing and innovation. Australia supports translational research and clinical trials. In Europe, Germany, France, Italy, Spain, and the United Kingdom each combine scientific and healthcare strengths with distinct reimbursement, procurement, and regulatory operating conditions. Russia has established scientific and pharmaceutical capabilities, while market access and supply considerations require careful assessment.

Strategic Priorities for Industry Leaders

Leaders should align molecule design with the full treatment pathway, including administration setting, patient adherence, cold-chain needs, and payer evidence requirements. They should build development platforms that connect computational design, laboratory validation, scalable manufacturing, and robust analytical comparability. Early planning for immunogenicity, formulation, device integration, and technology transfer can reduce later execution risks. Regional strategies should account for regulatory divergence, local evidence expectations, procurement structures, and supply resilience. Organizations should also establish governance for AI use, protect sensitive data, maintain human scientific oversight, and measure performance through clinically meaningful outcomes rather than technical novelty alone.

Research Methodology and Evidence Standards

This executive summary uses a structured qualitative assessment of bioengineered protein-drug development, manufacturing, regulation, access, and technology trends. The analysis is organized across the required regions, country groups, and countries, with attention to scientifically established characteristics of biologic therapeutics and documented healthcare-system differences. Claims are framed conservatively and avoid unsupported numerical estimates, market sizing, forecasts, market shares, or company-specific assertions. A rigorous market study should validate each conclusion against regulatory publications, peer-reviewed research, clinical registries, public procurement records, manufacturing disclosures, and country-level healthcare sources, while clearly distinguishing observed evidence from expert interpretation.

Conclusion: Building Resilient, Patient-Centered Protein Therapeutics

Bioengineered protein drugs are advancing through the combined influence of molecular engineering, bioprocess innovation, delivery improvements, data science, and evolving healthcare policy. Success will depend not only on discovering effective proteins but also on demonstrating durable clinical value, manufacturability, reliable supply, practical administration, and equitable access across varied healthcare systems. Organizations that integrate scientific rigor with regional execution, responsible AI governance, and patient-centered evidence generation will be better positioned to translate protein engineering into meaningful therapeutic outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Bioengineered Protein Drugs Market, by Drug Class
7.1. Introduction
7.2. Enzymes
7.2.1. Alglucosidase
7.2.2. Asparaginase
7.3. Fusion Proteins
7.4. Monoclonal Antibodies
7.4.1. Chimeric
7.4.2. Fully Human
7.4.3. Humanized
7.4.4. Murine
7.5. PEGylated Proteins
7.6. Recombinant Proteins
7.6.1. Erythropoietin
7.6.2. Growth Factors
7.6.3. Insulin
7.6.4. Interferons
8. Bioengineered Protein Drugs Market, by Therapeutic Indication
8.1. Introduction
8.2. Endocrinology
8.2.1. Diabetes Mellitus
8.2.2. Growth Disorders
8.3. Hematology
8.3.1. Anemia
8.3.2. Bleeding Disorders
8.4. Immunology
8.4.1. Inflammatory Bowel Disease
8.4.2. Psoriasis
8.4.3. Rheumatoid Arthritis
8.5. Infectious Diseases
8.5.1. Bacterial Infections
8.5.2. Viral Infections
8.6. Oncology
8.6.1. Hematological Malignancies
8.6.2. Solid Tumors
9. Bioengineered Protein Drugs Market, by Technology Platform
9.1. Introduction
9.2. Mammalian Cell Expression
9.3. Microbial Expression
9.4. Transgenic Host Expression
10. Bioengineered Protein Drugs Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Bioengineered Protein Drugs Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Care
11.4. Hospital
12. Bioengineered Protein Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Bioengineered Protein Drugs Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. European Union
13.5. BRICS
13.6. ASEAN
13.7. GCC
14. Bioengineered Protein Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. China
14.4. Germany
14.5. Japan
14.6. India
14.7. United Kingdom
14.8. France
14.9. Canada
14.10. Italy
14.11. Australia
14.12. South Korea
14.13. Brazil
14.14. Mexico
14.15. Russia
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Ambrx, Inc.
16.2. AMGEN INC.
16.3. Astrazeneca PLC
16.4. Baxter Healthcare
16.5. Bayer Pharmaceuticals
16.6. Bristol-Myers Squibb Company
16.7. CSL LTD.
16.8. F. Hoffmann-La Roche AG
16.9. GRIFOLS S.A.
16.10. GSK PLC
16.11. MERCK & CO., INC.
16.12. Novartis AG
16.13. Novo Nordisk A/S
16.14. Pfizer Inc.
16.15. Polaris Group
16.16. REGENERON PHARMACEUTICALS INC.
16.17. Sanofi SA
16.18. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Bioengineered Protein Drugs Market, Years Considered for the Study
FIGURE 2. Global Bioengineered Protein Drugs Market, Research Design
FIGURE 3. Global Bioengineered Protein Drugs Market, Research Framework
FIGURE 4. Global Bioengineered Protein Drugs Market, Data Triangulation
FIGURE 5. Global Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Bioengineered Protein Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Bioengineered Protein Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2025 vs 2032 (%)
FIGURE 9. Global Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Bioengineered Protein Drugs Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 11. Global Bioengineered Protein Drugs Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Bioengineered Protein Drugs Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Bioengineered Protein Drugs Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Bioengineered Protein Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Bioengineered Protein Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Bioengineered Protein Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Bioengineered Protein Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Bioengineered Protein Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Bioengineered Protein Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Bioengineered Protein Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Bioengineered Protein Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Bioengineered Protein Drugs Market Segmentation & Coverage
TABLE 2. Global Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Enzymes Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Enzymes Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Enzymes Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Alglucosidase Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Alglucosidase Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Alglucosidase Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Asparaginase Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Asparaginase Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Asparaginase Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Fusion Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Fusion Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Fusion Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Chimeric Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Chimeric Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Chimeric Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Fully Human Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Fully Human Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Fully Human Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Murine Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Murine Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Murine Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global PEGylated Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global PEGylated Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global PEGylated Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Recombinant Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Recombinant Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Recombinant Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Erythropoietin Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Erythropoietin Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Erythropoietin Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Growth Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Growth Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Growth Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Insulin Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Insulin Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Insulin Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Interferons Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Interferons Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Interferons Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 50. Global Endocrinology Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Endocrinology Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Endocrinology Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Diabetes Mellitus Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Diabetes Mellitus Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Diabetes Mellitus Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Growth Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Growth Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Growth Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Hematology Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Hematology Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Hematology Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Anemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Anemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Anemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Bleeding Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Bleeding Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Bleeding Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Inflammatory Bowel Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Inflammatory Bowel Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Inflammatory Bowel Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 99. Global Mammalian Cell Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Mammalian Cell Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Mammalian Cell Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Microbial Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Microbial Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Microbial Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Transgenic Host Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Transgenic Host Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Transgenic Host Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 109. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Europe Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Europe Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 145. Europe Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 146. Europe Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 147. Europe Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 148. Europe Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 149. Europe Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 150. Europe Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 151. Europe Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 152. Europe Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 153. Europe Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 154. Europe Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 155. Europe Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 156. Europe Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. North America Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. North America Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 159. North America Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 160. North America Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 161. North America Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 162. North America Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 163. North America Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 164. North America Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 165. North America Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 166. North America Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 167. North America Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 168. North America Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 169. North America Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 170. North America Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Latin America Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 172. Latin America Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 173. Latin America Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 174. Latin America Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 175. Latin America Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 176. Latin America Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 177. Latin America Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 178. Latin America Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 179. Latin America Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 180. Latin America Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 181. Latin America Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 182. Latin America Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 183. Latin America Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 184. Latin America Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Africa Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Africa Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 187. Africa Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 188. Africa Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 189. Africa Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 190. Africa Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 191. Africa Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 192. Africa Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 193. Africa Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 194. Africa Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 195. Africa Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 196. Africa Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 197. Africa Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 198. Africa Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Middle East Bioengineered Protein Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Middle East Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 201. Middle East Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 202. Middle East Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 203. Middle East Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 204. Middle East Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 205. Middle East Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 206. Middle East Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 207. Middle East Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 208. Middle East Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 209. Middle East Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 210. Middle East Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 211. Middle East Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 212. Middle East Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. Global Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. NATO Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. NATO Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 216. NATO Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 217. NATO Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 218. NATO Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 219. NATO Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 220. NATO Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 221. NATO Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 222. NATO Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 223. NATO Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 224. NATO Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 225. NATO Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 226. NATO Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 227. NATO Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. G7 Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 229. G7 Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 230. G7 Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 231. G7 Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 232. G7 Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 233. G7 Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 234. G7 Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 235. G7 Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 236. G7 Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 237. G7 Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 238. G7 Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 239. G7 Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 240. G7 Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 241. G7 Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. European Union Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. European Union Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 244. European Union Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 245. European Union Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 246. European Union Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 247. European Union Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 248. European Union Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 249. European Union Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 250. European Union Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 251. European Union Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 252. European Union Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 253. European Union Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 254. European Union Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 255. European Union Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. BRICS Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 257. BRICS Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 258. BRICS Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 259. BRICS Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 260. BRICS Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 261. BRICS Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 262. BRICS Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 263. BRICS Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 264. BRICS Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 265. BRICS Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 266. BRICS Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 267. BRICS Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 268. BRICS Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 269. BRICS Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. ASEAN Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 271. ASEAN Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. ASEAN Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 273. ASEAN Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 274. ASEAN Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 275. ASEAN Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 276. ASEAN Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 277. ASEAN Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 278. ASEAN Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 279. ASEAN Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 280. ASEAN Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 281. ASEAN Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 282. ASEAN Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 283. ASEAN Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. GCC Bioengineered Protein Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 285. GCC Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 286. GCC Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 287. GCC Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 288. GCC Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 289. GCC Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 290. GCC Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 291. GCC Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 292. GCC Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 293. GCC Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 294. GCC Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 295. GCC Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 296. GCC Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 297. GCC Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Global Bioengineered Protein Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 299. United States Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
TABLE 300. United States Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 301. United States Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 302. United States Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 303. United States Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 304. United States Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 305. United States Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 306. United States Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 307. United States Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 308. United States Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 309. United States Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 310. United States Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 311. United States Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 312. United States Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 313. China Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
TABLE 314. China Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 315. China Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 316. China Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 317. China Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 318. China Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 319. China Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 320. China Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 321. China Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 322. China Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 323. China Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 324. China Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 325. China Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 326. China Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. Germany Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
TABLE 328. Germany Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 329. Germany Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 330. Germany Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 331. Germany Bioengineered Protein Drugs Market Size, by Recombinant Proteins, 2017-2032 (USD Million)
TABLE 332. Germany Bioengineered Protein Drugs Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
TABLE 333. Germany Bioengineered Protein Drugs Market Size, by Endocrinology, 2017-2032 (USD Million)
TABLE 334. Germany Bioengineered Protein Drugs Market Size, by Hematology, 2017-2032 (USD Million)
TABLE 335. Germany Bioengineered Protein Drugs Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 336. Germany Bioengineered Protein Drugs Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 337. Germany Bioengineered Protein Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 338. Germany Bioengineered Protein Drugs Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 339. Germany Bioengineered Protein Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 340. Germany Bioengineered Protein Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 341. Japan Bioengineered Protein Drugs Market Size, 2017-2032 (USD Million)
TABLE 342. Japan Bioengineered Protein Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 343. Japan Bioengineered Protein Drugs Market Size, by Enzymes, 2017-2032 (USD Million)
TABLE 344. Japan Bioengineered Protein Drugs Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 345. Japa

Companies Mentioned

  • Ambrx, Inc.
  • AMGEN INC.
  • Astrazeneca PLC
  • Baxter Healthcare
  • Bayer Pharmaceuticals
  • Bristol-Myers Squibb Company
  • CSL LTD.
  • F. Hoffmann-La Roche AG
  • GRIFOLS S.A.
  • GSK PLC
  • MERCK & CO., INC.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Polaris Group
  • REGENERON PHARMACEUTICALS INC.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Bioengineered Protein Drugs - Global Strategic Business Report - Product Image

Bioengineered Protein Drugs - Global Strategic Business Report

  • Report
  • 617 Pages
  • Global
From
Bioengineered Protein Drugs Market Report 2026 - Product Image

Bioengineered Protein Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bioengineered Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Bioengineered Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Protein Therapeutics Market - Global Forecast 2026-2032 - Product Image

Protein Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Protein Therapeutics - Global Strategic Business Report - Product Image

Protein Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.